A real-world analysis investigates the impact of concurrent GLP-1 RA use on long-term survival and the safety profile of patients with solid and hematologic malignancies receiving immune checkpoint ...
When it comes to cancer metastasis, it takes two to tango. That was one of the key findings of a new study led by researchers at Memorial Sloan Kettering Cancer Center (MSK): The TGF-beta and RAS ...
Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.
Clinical Trials Arena on MSN
Revolution’s RAS inhibitor pipeline posts more pancreatic cancer trial wins
The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic ...
PHILADELPHIA — The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with a significant decrease in the risk for early-onset colorectal cancer (EO-CRC) in patients with type 2 ...
A new study from Sweden cautions against routine discontinuation of renin-angiotensin system (RAS) inhibitors in patients with chronic kidney disease (CKD). A new study from Sweden cautions against ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results